Coluccia M, Giordano D, Loseto F, Intini F P, Maresca L, Natile G
Istituto di Patologia Generale, Bari, Italy.
Anticancer Res. 1989 May-Jun;9(3):795-8.
The ability of enantiomeric platinum complexes to block the action of selected restriction enzymes has been investigated. The complexes [PtCl2(DAC)], [PtCl2(DAB)] and [PtCl2(DAP)] (DAC = 1,2-diamminocyclohexane; DAB = 2,3-diamminobutane; DAP = 1,2-diamminopropane) exhibit a guanine-cytosine preference in accord with previous results on cis-[PtCl2(NH3)2] (cis-DDP). The extent of inhibition, however, is significantly different for the different isomers; the R,R form is more active than the others at short incubation time, as the time becomes longer, the differences among isomers level off. It also appears that cis-DDP is more active than [PtCl2(DAC)] in blocking the Cfo I enzyme, though it shows a preference for the G-X-G sequences.
对映体铂配合物阻断所选限制酶作用的能力已得到研究。配合物[PtCl2(DAC)]、[PtCl2(DAB)]和[PtCl2(DAP)]（DAC = 1,2 - 二氨基环己烷；DAB = 2,3 - 二氨基丁烷；DAP = 1,2 - 二氨基丙烷）表现出鸟嘌呤 - 胞嘧啶偏好性，这与之前关于顺式[PtCl2(NH3)2]（顺铂）的结果一致。然而，不同异构体的抑制程度有显著差异；在短孵育时间时，R,R形式比其他形式更具活性，随着时间延长，异构体之间的差异趋于平稳。似乎顺铂在阻断Cfo I酶方面比[PtCl2(DAC)]更具活性，尽管它对G - X - G序列表现出偏好性。
